J. Munoz-Basagoiti

The paper identifies beta-cyclodextrins as effective and affordable antivirals against SARS-CoV-2 and other coronaviruses through molecular modeling and in vitro testing.

This paper identifies mutations that improve the production and efficacy of SARS-CoV-2 Spike proteins, protecting animal models from the Beta variant.

This study uses electron microscopy to show plitidepsin blocks SARS-CoV-2 replication organelles and virus morphogenesis.

This study shows that the SARS-CoV-2 B.1.351 variant infects K18-hACE2 mice faster and wildtype mice, with milder symptoms than the B.1 variant.

This study shows that CPC-containing mouthwashes significantly reduce SARS-CoV-2 infectivity in vitro across variants by disrupting the viral envelope and inhibiting fusion.

This study screens existing drugs to identify potent inhibitors of SARS-CoV-2-induced cytopathic effect and viral replication, finding plitidepsin as the most effective clinically approved drug.